Introduction: Central nervous system (CNS) metastases in lung cancer are a frequent cause of morbidity and mortality. There are conflicting data on the incidence of CNS metastases in stage IV ROS1-positive NSCLC and the rate of CNS progression during crizotinib therapy.
Introduction
Rearrangement of the ROS1 receptor tyrosine kinase gene has been identified as an oncogenic driver, occurring in approximately 1% to 2% of NSCLC cases.
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Rearrangement commonly leads to the creation of chimeric fusion genes that promote an oncogenic phenotype through constitutive activation of the ROS1 kinase activity. 3 Preclinical studies and clinical trials have demonstrated that crizotinib, a small molecule tyrosine kinase inhibitor (TKI), demonstrates activity against both ALK receptor tyrosine kinase gene (ALK) and ROS1 rearrangements. 1, [3] [4] [5] [6] Crizotinib is approved by regulatory agencies worldwide as a first-line agent for treatment of ROS1-positive NSCLC. Several nextgeneration inhibitors with activity against ROS1 are also under investigation. [7] [8] [9] Brain metastases remain a major cause of morbidity and mortality in patients with NSCLC. It is estimated that in 25% to 40% of patients with NSCLC, brain metastases develop during the course of their disease. 10 Despite many clinical similarities between patients with ALK receptor tyrosine kinase (ALK)-positive NSCLC and those with ROS1-positive NSCLC, there remain conflicting data regarding the incidence of brain metastases in treatment-naive ROS1-positive NSCLC. In contrast to ALK-positive NSCLC, in which the incidence of brain metastases in the treatment-naive population has been reported to range between 25% and 30%, [11] [12] [13] [14] [15] there remains wide variability in the reported incidence of brain metastases for ROS1-positive NSCLC. [16] [17] [18] Although excellent systemic responses to crizotinib therapy are seen in patients with ALK-positive NSCLC, central nervous system (CNS) progression is common owing to the reduced penetrance of crizotinib through the blood-brain barrier. 4, 12 This can be mitigated by newer-generation TKIs such as ceritinib, 8 alectinib, 19 and brigatinib, 20 all of which are U.S. Food and Drug Administration-approved for ALK-positive NSCLC. The median progression-free survival (PFS) time with crizotinib in advanced ALK-positive NSCLC is consistently reported across different studies as being between 8 and 11 months. [12] [13] [14] [15] 21 The initial report on crizotinib therapy in ROS1-positive NSCLC demonstrated a median PFS of 19 months, 6 though a recent large phase II study of patients with ROS1-positive NSCLC during crizotinib therapy reported a lower median PFS of 15 months. 18 One potential explanation for the difference in PFS between the ROS1-positive and ALK-positive populations is that if ROS1-positive NSCLC had a lower tropism for the CNS than ALK-positive NSCLC does, then the CNS liability of crizotinib would be less apparent. 6, 16 An alternative hypothesis is that crizotinib has increased potency (a lower concentration that inhibits 50%) against ROS1 than against ALK, which would allow a lower dose of crizotinib in the CNS to inhibit ROS1-positive cancer cells more effectively than ALK-positive cancer cells. 22, 23 In this single-center retrospective series, we recorded the incidence of brain metastases in stage IV ROS1-positive NSCLC and compared this incidence to that in cohorts with other oncogene mutations, including ALK, EGFR, KRAS, BRAF, and other mutations. On the basis of a prior study showing no difference in the incidence of brain metastases between patients with metastatic NSCLC and EGFR, ALK, and KRAS mutations, our hypothesis was that the incidence of brain metastases in ROS1-positive NSCLC was not significantly different from that with other oncogene subtypes. 11 Additionally, we explored the rate of CNS progression (P-CNS) in the ROS1-positive and ALK-positive cohorts during crizotinib therapy. We chose ALK-positive NSCLC as a comparator to ROS1-positive NSCLC because crizotinib is an approved first-line therapy for both groups.
Material and Methods
Incidence of Brain Metastases in TreatmentNaive Stage IV NSCLC All patients with NSCLC (classified according to the seventh edition of the TNM staging system) who were evaluated at the University of Colorado from June 2008 to December 2017 were eligible for assessment. A protocol approved by the institutional review board permits clinical correlates to be made for all patients in whom molecular analyses have been conducted within the Colorado Molecular Correlates Laboratory or for whom we have written documentation of testing performed at outside facilities. Patients were identified by using a database that included all patients treated through the University of Colorado Health System. The patient population contained a mix of patients whose NSCLC was diagnosed and treated within the University of Colorado Health System and patients who were treated in the community and subsequently referred to our institution.
Outcomes data and imaging results were collected by retrospective chart review. We captured age, sex, smoking status, histologic type, and clinical stage at diagnosis. We captured brain metastases at time of diagnosis of stage IV disease through clinical review and review of baseline neuroimaging. All patients considered for analysis had magnetic resonance imaging of the brain at time of diagnosis of stage IV disease. For each patient included in this analysis, we captured oncogene status; patients were divided into the following cohorts: ROS1, ALK, EGFR, KRAS, and BRAF. Patients with no identifiable oncogene or with a driver mutation that did not fall into one of the aforementioned categories were grouped in a separate cohort. For the ROS1 cohort, we identified the method used to detect the ROS1 rearrangement. If available, we noted the ROS1 gene fusion partner for each patient. Patients with squamous histologic features, incomplete neuroimaging assessment at diagnosis of stage IV disease, incomplete clinical data, or no documented mutation testing were excluded ( Supplementary  Fig. 1 ).
P-CNS of ROS1-Positive and ALK-Positive NSCLC during Crizotinib Therapy
We defined treatment-naive patients as those who had not received any systemic therapy and TKI-naive patients as those who had not received TKI therapy. For the ROS1-positive and ALK-positive cohorts during crizotinib therapy, we noted whether patients progressed first in the CNS, progressed systemically, or progressed both in the CNS and systemically. We captured PFS and time to P-CNS. PFS was defined as the duration of time from the start of crizotinib therapy to first radiographic progression or death in the absence of documented progression. Patients who remained alive without documented disease progression were censored on the last follow-up date. P-CNS was defined as the duration of time from the start of crizotinib therapy to first radiographic documentation of P-CNS. We captured whether patients received brain radiotherapy and prior chemotherapy, as these were potential confounders. When P-CNS was compared between the ALK-positive and ROS1-positive cohorts, patients were excluded if they never received crizotinib, if there were no follow-up data after they had started taking crizotinib, or if they had received newer-generation TKIs as first-line therapy.
Molecular Methods for Mutation and Rearrangement Testing
Molecular testing was conducted by Clinical Laboratory Improvement Amendments-certified laboratories and performed with use of laboratory assays that had been independently validated. Over the course of this study, the testing approach for standard of care laboratory testing evolved, as a result of which testing was performed by using a variety of assay platforms. These approaches included Sanger sequencing of relevant targeted regions, single-nucleotide base extension assay (SNaPshot, Parabon NanoLabs, Reston, VA), realtime polymerase chain reaction, and targeted nextgeneration sequencing (NGS) using a 26-gene panel (TruSight, Illumina, San Diego, CA) or the Archer FusionPlex Solid Tumor library preparation kit (ArcherDx, Boulder, CO) with raw sequence data analyzed by using the Archer Analysis software package (version 4.1.1.7; ArcherDx). Evaluation of gene fusions such as ALK and ROS1 were performed by a variety of techniques, including (1) fluorescence in situ hybridization (FISH) using break-apart probes as previously described [24] [25] [26] ; (2) FISH testing using the Abbott Vysis ALK Break-Apart Probe (Abbott Molecular, Abbott Park, IL) or immunohistochemistry using the Ventana ALK (D5F3) CDX assay (Ventana Medical Systems, Tucson, AZ); or (3) fusion NGS testing utilizing Archer FusionPlex run with analysis software (version 4.1.1.7). For internally tested cases, FISH was performed on 4-mM (± 1-mM)-thick formalin-fixed, paraffin-embedded tumor sections. The ROS1 FISH probes used for these cases included Vysis (Abbott Molecular) and custom-designed probes. FISH assays were performed as previously described or by using the Vysis Paraffin Pretreatment IV and PostHybridization Wash Buffer Kit (Abbott Molecular) per the manufacturer's instructions. Signals were evaluated in at least 50 tumor nuclei per specimen. Specimens were considered positive for ROS1 rearrangement if at least 15% of cells displayed a split 5 0 /3 0 and/or single 3 0 signal pattern. Separation between 5 0 and 3 0 ROS1 signals of at least 1 signal diameter was required for scoring as a split pattern. In some cases of samples that were tested by outside laboratories, information regarding the specific FISH probes was not available.
Statistical Testing
To compare the incidence of brain metastases in treatment-naive patients between oncogene groups, a Fisher exact test was used to compare the proportion of patients with brain metastasis at diagnosis of stage IV disease to the proportion of patients without brain metastasis at diagnosis of stage IV disease. Similarly, the Fischer exact test was used to assess differences in incidence of brain metastases between CD74 molecule gene (CD74)-ROS1 gene fusions and non-CD74-ROS1 gene fusions. Kaplan-Meier curves and estimates were used to assess PFS and P-CNS during crizotinib therapy for ROS1-positive and ALK-positive NSCLC. Differences in PFS and time to P-CNS were assessed by using a logrank test. All statistics were generated with GraphPad Prism software (version 6.00 for Windows, GraphPad Software, La Jolla, CA) and R (version 3.4.3 for Windows, R Project, Vienna, Austria).
Results
Clinical Characteristics
A total of 689 patients were considered for this study. Of these, 110 were excluded on the basis of the exclusion criteria described earlier, with 579 patients included for further analysis (Supplemental Fig. 1 ). When mutations were subdivided by oncogene, we identified 33 ROS1, 115 ALK, 192 EGFR, 102 KRAS, and 16 BRAF mutations. Patients with no identifiable driver oncogene or with a mutation that did not fit into the aforementioned categories (n ¼ 121) were grouped separately. Baseline clinical characteristics for each of the oncogene groups are listed in Table 1 . The methods used for detecting the ROS1 gene rearrangement were as follows: FISH, which was used in 39% of patients (13 of 33); reversetranscriptase polymerase chain reaction, which was used in 3% of patients (one of 33); and NGS, which was used in 56% of patients (19 of 33) . Fusion partner data were available for 17 ROS1-positive patients with the following distribution: CD74-ROS1, in 12 of 17 patients, SLC34A2-ROS, in four of 17 patients, and ZCCHC8-ROS1, in one of 17 patients. Of note, 45% of patients with ROS1-positive NSCLC (15 of 33) had their ROS1 rearrangement diagnosed internally and 55% (18 of 33) had theirs diagnosed at outside institutions. The median age of those in the ROS1-positive cohort was 55 years. The median number of pack-years of cigarette smoking was zero (range 0-45).
The percentages of brain metastases at diagnosis of stage IV NSCLC per oncogene group were as follows: ROS1, 36% (12 of 33); ALK, 34% (39 of 115); EGFR, 28% (53 of 192); KRAS, 28% (29 of 102); BRAF, 19% (three of 16); and other, 22% (26 of 121). There were no statistically significant differences in the incidence of brain metastases in patients with metastatic ROS1-positive NSCLC when compared with each of the other oncogene groups (Fig. 1) . In all, 42% percent of CD74-ROS1 gene fusions (five of 12) and 60% of non-CD74-ROS1 fusions (three of five) had brain metastases at diagnosis of stage IV disease. There were no statistically significant differences in the percentage of brain metastases at diagnosis of stage IV disease between the CD74-ROS1 and non-CD74-ROS1 fusions (p ¼ 0.620). (10) 5 (15) 20 (17) 7 (4) 10 (10) Incidence of brain metastases across oncogene groups. The incidence of brain metastases at diagnosis of stage IV disease as separated by oncogene. The Fisher exact test was used to assess for statistically significant differences between ROS1 and other oncogene cohorts. The incidence of brain metastases in treatment-naive patients with ROS1-positive NSCLC was 36%. There were no statistically significant differences in the incidence of brain metastases at diagnosis of stage IV disease across oncogene cohorts. ALK, ALK receptor tyrosine kinase.
P-CNS in ROS1-Positive and ALK-Positive NSCLC during Crizotinib Therapy
A total of 33 ROS1-positive patients and 115 ALKpositive patients were considered for this analysis. A consort diagram demonstrating exclusion criteria is shown in Figure 2 . A total of 19 ROS1-positive patients and 83 ALK-positive patients were eligible for analysis of P-CNS during crizotinib therapy. Baseline clinical characteristics for ROS1-positive and ALK-positive patients are shown in Figure 2 . The median durations of follow-up were 30 months and 47 months for the ROS1-positive and ALK-positive cohorts, respectively. The percentages of patients who received chemotherapy and radiotherapy before crizotinib are shown in Figure 2 . The pre-TKI therapy rates of brain metastases for the ROS1-positive and ALK-positive patients included in this analysis were 11% (two of 19) and 33% (27 of 83), respectively. The incidence of pre-TKI therapy brain metastases among patients excluded from this analysis is shown in Figure 2 . Among the ROS1-positive patients who were excluded because of enrollment in a clinical trial, the pre-TKI therapy incidence of brain metastases was 57% (four of seven).
A total of 95 patients (16 ROS1-positive and 79 ALK-positive patients) progressed during crizotinib therapy. The median treatment durations for all ROS1-positive and ALK-positive patients in this analysis were 11 months and 13 months, respectively. The PFS times for the ROS1-positive and ALK-positive cohorts are shown in Figure 3 . The median PFS times for the ROS1-positive cohort and ALK-positive cohorts were 11 months (95% confidence interval [CI]: 8-23) and 8 months (95% CI: 7-13) respectively, with no statistically significant differences between these groups (p ¼ 0.304) (Fig. 3A) . Among patients who received crizotinib in the second-line setting, the median PFS times for ROS1-positive NSCLC and ALK-positive NSCLC were 15 months (95% CI: 7-not achieved) and 11.5 months (95% CI: 8-14), respectively, with no significant differences between the two groups (p ¼ 0.202) (Fig. 3B) . The upper limit of the 95% confidence interval was not reached for ROS1-positive NSCLC in the second-line setting.
The CNS was the first and sole site of progression in 47% of ROS1-positive patients (nine of 19) and 33% of ALK-positive patients (28 of 83), with no statistically significant differences between these groups (p ¼ 0.610) (see Fig. 2 ). P-CNS during crizotinib therapy is demonstrated in Figure 4 . Among all patients, P-CNS was not significantly different between the ROS1-positive and ALK-positive groups (p ¼0.222) (Fig. 4A) . When the analysis was limited to patients who did not have brain metastases before receiving crizotinib, P-CNS was not significantly different between the ROS1-positive and ALK-positive groups (p ¼ 0.908) (Fig. 4B) k All of these data were captured while patients were undergoing crizotinib therapy.
21 months, 50% of ROS1-positive and ALK-positive patients without brain metastases before crizotinib therapy had progressed within the CNS, respectively.
Given that prior chemotherapy could be a confounding variable, we ran a separate analysis to explore P-CNS in ROS1-positive (n ¼ 8) and ALK-positive (n ¼ 27) patients who received crizotinib as first-line systemic therapy. In this subset, 12% patients with ROS1-positive NSCLC (one of eight) and 40% of ALKpositive patients with NSCLC (eight of 20) had brain metastases at the time of diagnosis of stage IV disease. The percentages of ROS1-positive and ALK-positive patients undergoing first-line crizotinib who progressed within the CNS alone were 63% (five of eight) and 22% (six of 27), with no significant differences between the groups (p ¼ 0.07) (Fig. 5 ). Brain radiosurgery was also a potential confounding variable in our data. We determined whether patients received brain radiosurgery at any point from time of diagnosis to cessation of crizotinib therapy. In this subset, none of the ROS1-positive patients and 40% of the ALK-positive patients (eight of 20) received brain radiosurgery. There was no difference in cumulative incidence of P-CNS between these two groups (p ¼ 0.556) (see Fig. 5 ). The median durations of follow-up for ROS1-positive patients with NSCLC and ALK-positive patients with NSCLC who received first-line crizotinib were 16 months and 8 months, respectively.
Discussion
Our data demonstrate that brain metastases are common in patients with stage IV, treatment-naive, ROS1-positive NSCLC, which contrasts with the findings of other studies that report a reduced incidence of brain metastasis. 16, 17 In the EUROS1 cohort, 31 ROS1-positive NSCLC were retrospectively identified, with 3.2% of patients (one of 31) having brain metastases at time of diagnosis of stage IV disease. 17 In a phase II study of ceritinib therapy in patients with ROS1 rearrangements, 25% of patients (eight of 32) were found to have brain metastases before treatment with ceritinib, but the percentage of patients with brain metastases at time of stage IV disease was not reported. 27 A multicenter phase II trial study of crizotinib in East Asian patients with ROS1-positive NSCLC found that 18% of those patients (23 of 117) had brain metastases at baseline. 18 It is worth noting that in this study, patients with brain metastases were eligible only if they were asymptomatic or were neurologically stable for 2 weeks if treated. Another recent single-institution series of 39 patients with ROS1-positive NSCLC found a lower prevalence of brain metastases at the time of metastatic diagnosis than in a cohort with ALK-positive NSCLC (19.4% versus 39.1%, respectively). 16 In our study, the baseline incidences of brain metastases in ROS1-positive and ALK-positive NSCLC were 36% and 34%, respectively. There were no statistically significant differences between the incidence of brain metastasis in ROS1-positive NSCLC and that in other oncogene subsets. Although the percentage of ROS1-positive NSCLC cases included in this study is higher than the reported incidence in the general population (6% versus 1%-2%), the number of ROS1-positive patients in our study is comparable to the numbers in other large scale studies at tertiary referral centers. [16] [17] [18] Although differences in patterns of metastatic spread have been observed between oncogene subgroups in NSCLC, 11 the data presented here suggest that the propensity toward brain metastases is independent of the oncogene, which is consistent with the findings of other studies demonstrating no statistically significant difference in the incidence of brain metastases between ALK, EGFR, KRAS, or other oncogenes. 11, 28 The data presented here extend this finding to ROS1 and BRAF oncogene subsets.
When we analyzed the incidence of brain metastases on the basis of ROS1 fusion partners, we found that 42% percent of patients with CD74-ROS1 gene fusions (five of 12) and 60% of those with non-CD74-ROS1 gene fusions (three of five) had brain metastases at diagnosis of stage IV disease, a finding that is in contrast with those of a recent study that noted a higher incidence of brain metastases in patients with the CD74-ROS1 gene fusion. 29 Because CD74-ROS1 is the most common gene rearrangement, it remains possible that the higher incidence of brain metastases noted may simply reflect the underlying prevalence of the CD74-ROS1 gene fusion. Given our limited sample size, our study was not powered to detect differences between gene fusions and time to P-CNS during crizotinib therapy, though a recent study found no differences in P-CNS between patients with CD74-ROS1 and those with non-CD74-ROS1 gene fusions. 29 It is relevant to note that a univariate analysis in this study did identify brain metastases as a significant risk factor for PFS during crizotinib therapy. Future studies examining differences in ROS1 gene fusions and propensity for P-CNS during TKI therapy are warranted.
The incidence of brain metastases for the ROS1-positive patients included for the P-CNS analysis was markedly lower than that in the ALK-positive group (11% versus 33%). We attribute this difference in percentage to the significant number of otherwise-eligible patients with ROS1-positive NSCLC who were enrolled in clinical trials with CNS-penetrant TKIs and were thereby excluded from this analysis. When we analyzed the excluded ROS1-positive patients from this study, 71% (10 of 14) had brain metastases at stage IV disease, and the exclusion of these patients from the crizotinib-treatment analyses accounts for the baseline differences in brain metastases between the ROS1-positive and ALK-positive cohorts.
Among patients without CNS metastases before crizotinib therapy, 50% of ROS1-positive and ALK-positive patients experienced metastases in the CNS as only site of progression after 24 and 21 months of therapy, suggesting that brain metastases can occur quite late in the course of treatment with crizotinib. This frequent P-CNS was observed in the ROS1-positive cohort despite the lower percentage of patients with brain metastases at initiation of crizotinib therapy, which suggests that although crizotinib can be quite effective in maintaining systemic control, poor penetration across the bloodbrain barrier with resultant CNS metastatic spread remains a major source of morbidity for both ROS1-positive and ALK-positive NSCLC.
Prior systemic and radiotherapy were potential confounders in our analysis of P-CNS during crizotinib therapy. We compared the incidence of CNS metastases in ROS1-positive and ALK-positive patients who received crizotinib as first-line systemic therapy. We found that 63% of ROS1-positive patients and 22% of ALK-positive patients who received first-line crizotinib had P-CNS as the first and only site of progression, with no significant differences between these groups (p ¼ 0.07). Our small sample size for these subset analyses limits the strength of these conclusions. Recent studies have shown improved outcomes for radiosurgery in patients with ALK oncogene-or EGFR oncogene-addicted NSCLC. 30 None of our ROS1-positive patients who received first-line crizotinib (n ¼ 8) received brain radiotherapy. In this subset, 63% of ROS1-positive patients receiving crizotinib (five of eight) progressed in the CNS alone. In contrast, 40% of ALK-positive patients (eight of 20) had received prior brain radiotherapy, and 22% of these patients (six of 27) progressed in the CNS alone. It is therefore possible that the differences in P-CNS between our ROS1-positive and ALK-positive cohorts might be due to the percentage of ALK-positive patients who received brain radiotherapy before crizotinib therapy. This possibility is consistent with the findings of prior studies in which local ablative strategies in oncogene-addicted NSCLC have demonstrated disease control. 31 There are several limitations to our study. Despite the accrual of a cohort of ROS1-positive patients comparable to those in multiple other large studies, our sample size was not large enough to permit performance of a multivariable analysis to adjust for potential confounders such as number of lines of prior therapy, duration of therapy, and treatment of brain metastases with radiation. We attempted to evaluate some of these potential confounders through stratified analyses, but larger-scale studies utilizing shared institutional
